Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
1
14%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Terminated(1)
Other(4)

Detailed Status

unknown4
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed229%
unknown457%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
terminated

Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.

NCT04322279
unknown

Investigation Into the Microorganisms in Pregnant Women

NCT04688866
completednot_applicable

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

NCT01543113
unknown

Biomarkers of Response to Systemic Treatments in FH-deficient RCC

NCT05243173
unknown

Genetic Diversity of Toxoplasma Gondii in Cancer Patients

NCT04834076
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04322279

Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.

Terminated
NCT04688866

Investigation Into the Microorganisms in Pregnant Women

Unknown
NCT01543113Not Applicable

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Completed
NCT05243173

Biomarkers of Response to Systemic Treatments in FH-deficient RCC

Unknown
NCT04834076

Genetic Diversity of Toxoplasma Gondii in Cancer Patients

Unknown
NCT04213313

Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis

Completed
NCT02843711

Molecular Analysis of 150 Lung Adenocarcinoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7